Donor cells join fight against tough breast cancer
NCT ID NCT05385705
Summary
This early study tested whether adding donor immune cells (natural killer cells) to standard breast cancer drugs could help patients with advanced HER2-positive breast cancer that had stopped responding to previous treatments. The goal was to see if this combination was safe and showed any signs of fighting the cancer. The trial was terminated early after enrolling only 2 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital del Mar
Barcelona, 08003, Spain
-
Vall d'Hebron Hospital
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.